Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy variable 3-7 (IGHV3-7) is a gene segment encoding the variable (V) region of the heavy chain of immunoglobulins (antibodies)[1][4][5]. This V region participates in the formation of the antigen-binding site of the antibody by combining with diversity (D) and joining (J) gene segments through a DNA rearrangement process specific to B cell development[2]. The protein product is part of the variable domain of the immunoglobulin heavy chain, critical for recognizing and binding specific antigens[1][5]. Membrane-bound immunoglobulin molecules function as B cell receptors, while secreted forms mediate antigen elimination as antibodies[2]. IGHV3-7 itself is not a drug target, but rather one of many gene segments contributing to antibody diversity[1][5]. Changes in IGHV3-7 sequence or usage can reflect or contribute to immune repertoire diversity and have indirect associations with immune disorders, but it is not considered a standalone receptor or therapeutic target[1][4][5][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin heavy variable 3-7 (IGHV3-7).